Home / Deep Research / Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome

Wiskott-Aldrich Syndrome Research Fallback

⚠️ Fallback MONDO:0010518

Wiskott-Aldrich Syndrome Research Fallback

Deep-research provider attempts were made after selecting the direct Orphanet/MONDO target ORPHA:906 / MONDO:0010518:

  • timeout 180 just research-disorder falcon Wiskott_Aldrich_Syndrome
  • timeout 180 just research-disorder openai Wiskott_Aldrich_Syndrome
  • timeout 90 just research-disorder openai Wiskott_Aldrich_Syndrome was retried after PR review requested a fresh deep-research attempt.

All provider commands printed the initial provider line, then stalled without producing a completed research output file and were terminated by their timeouts. The curation therefore intentionally used the structured Orphanet cache plus fetched PubMed cache records as the auditable evidence base, with all added phenotype and treatment statements backed by exact snippets from those caches.

Literature Scope Checked

  • references_cache/ORPHA_906.md: direct Orphanet disease record for Wiskott-Aldrich syndrome, including definition, X-linked recessive inheritance, exact MONDO and OMIM mappings, prevalence, age of onset, WAS disease-gene assertion, and HPO phenotype rows.
  • references_cache/PMID_7579347.md: human molecular study showing that Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same WAS gene, with classic WAS linked to complex mutations such as termination codons and frameshifts.
  • references_cache/PMID_10523789.md: review supporting WAS as a disorder of hematopoietic actin-cytoskeleton regulation, including membrane-to-actin signal transduction and defects in cell polarization and motility.
  • references_cache/PMID_19628299.md: review supporting defective immune-cell migration, antigen uptake, activation, and host defense due to WASp deficiency.
  • references_cache/PMID_28805251.md: review supporting WASp roles in innate and adaptive immunity, including immune synapse formation, cell signaling, migration, cytokine release, regulatory T and B cell defects, and B-cell selection abnormalities.
  • references_cache/PMID_26159751.md: clinical treatment review supporting life-threatening disease burden, bleeding tendency, eczema, autoimmunity, malignancy risk, hematopoietic stem cell transplantation, gene therapy, and management of pre- and post-transplant complications.
  • references_cache/PMID_21659547.md: retrospective collaborative human HCT cohort of 194 patients supporting survival outcomes, chimerism, and persistent thrombocytopenia risk when myeloid donor chimerism is low.
  • references_cache/PMID_8957959.md: retrospective human supportive-care series directly supporting IVIG with antibiotic prophylaxis in Wiskott-Aldrich syndrome.

Curation Conclusions

  • Disease identity is the syndrome-level disorder ORPHA:906, exact to MONDO:0010518 and OMIM:301000.
  • The primary mechanism is WAS pathogenic variation causing deficient or dysfunctional WASp in hematopoietic cells.
  • WASp dysfunction disrupts actin cytoskeleton organization and membrane-to- actin signaling, producing impaired immune-cell migration, antigen uptake, activation, immune synapse function, signaling, cytokine release, and host defense.
  • Platelet involvement is represented as microthrombocytopenia with abnormal platelet morphology, prolonged bleeding time, bruising, hematomas, and internal hemorrhage.
  • Orphanet directly supports the curated very-frequent phenotypes: immunodeficiency, recurrent respiratory infections, sinusitis, otitis media, chronic otitis media, thrombocytopenia, abnormal platelet morphology, prolonged bleeding time, bruising susceptibility, spontaneous hematomas, internal hemorrhage, decreased total lymphocyte count, fever, chronic diarrhea, and chronic pulmonary obstruction.
  • Orphanet also directly supports all curated frequent phenotypes in the cached ORPHA:906 table: petechiae, purpura, specific learning disability, hemolytic anemia, abnormality of eosinophils, anemia, microcytic anemia, inflammation of the large intestine, dyspnea, hematemesis, hematochezia, autoimmunity, arrhythmia, and fatigue.
  • Additional evidence-backed features include eczematoid dermatitis and lymphoma.
  • Evidence-backed treatments are hematopoietic stem cell transplantation, emerging gene therapy, supportive management of infections, bleeding, eczema, autoimmunity, and transplant-related complications, and IVIG prophylaxis.